Compare JFU & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFU | SKYE |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.5M | 44.9M |
| IPO Year | 2018 | 2013 |
| Metric | JFU | SKYE |
|---|---|---|
| Price | $4.55 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 5.5K | ★ 233.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 86.41 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $0.68 |
| 52 Week High | $9.48 | $5.75 |
| Indicator | JFU | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 40.95 |
| Support Level | $4.12 | $0.68 |
| Resistance Level | $5.66 | $0.83 |
| Average True Range (ATR) | 0.34 | 0.05 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 23.78 | 36.18 |
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.